Tharimmune announces scientific advisory board to drive clinical-stage lead in chronic liver disease and early-stage tunable knob domains for generating antibody drug conjugate (adc) biotherapeutics

Group includes leading experts in multiple disciplines including immunology, liver diseases, protein engineering, antibody drug conjugates and platform innovation bridgewater, nj / accesswire / april 15, 2024 / tharimmune, inc. (nasdaq:thar) ("tharimmune" or the "company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology announced today the formation of a new scientific advisory board (sab) that includes a group of leading experts in fields spanning immunology, liver disease clinical trials, protein engineering, antibody drug conjugates as well as knob domains, the smallest antibody like fragments. "tharimmune's mission is to advance immunology and oncology treatments for people suffering from high unmet need conditions and help them look forward to a better tomorrow," said randy milby, chief executive officer of tharimmune.
THAR Ratings Summary
THAR Quant Ranking